BB Adamant Biotech (Lux)

Biotech sector with sustainable, strong sales and earnings growth thanks to high innovation level 

 Expiring patents of pharma companies lead to high M&A activity (patent cliff)

 Valuations very attractive on historical average over the last 10 years

Please select a share class.

Please find a more detailed description of share classes here.

Investment Focus

ISIN-No. LU0415392751

The Fund invests worldwide in companies active in the biotechnology sector. Experienced sector specialists focus on profitable mid- and large-cap companies with an established product portfolio. Stock selection is based on fundamental analysis. The selection of portfolio companies is entirely bottom-up, independent of benchmark weightings.

Indexed performance (as at: 22.10.2021)

NAV: USD 693.89 (21.10.2021)


Fonds (Brutto)
01 Jan 2010 - 01 Jan 2010
An error occurred - no data to display

Rolling performance (21.10.2021)

I-USDBenchmark
21.10.2020 - 21.10.202117.62%17.59%
21.10.2019 - 21.10.202028.91%29.30%
21.10.2018 - 21.10.2019-4.79%-6.68%
21.10.2017 - 21.10.2018-5.22%-0.36%

Annualized performance (21.10.2021)

I-USDBenchmark
1 year17.62%17.59%
3 years12.98%12.33%
5 years11.95%12.11%
Since Inception p.a.14.61%17.10%

Cumulative performance (21.10.2021)

I-USDBenchmark
1M-5.00%-6.85%
YTD4.98%4.26%
1 year17.62%17.59%
3 years44.37%41.89%
5 years75.91%77.15%
Since Inception455.11%626.68%

Annual performance

I-USDBenchmark
202023.88%25.69%
201928.76%24.41%
2018-14.57%-9.32%
201724.04%21.06%

Investment Focus

The Fund invests worldwide in companies active in the biotechnology sector. Experienced sector specialists focus on profitable mid- and large-cap companies with an established product portfolio. Stock selection is based on fundamental analysis, in particular of the medical indications addressed, the means of efficacy and the market potential. A global network of experts spanning scientific and industrial fields supports the Management Team in forming opinions and making investment decisions. The selection of portfolio companies is entirely bottom-up, independent of benchmark weightings.Show moreShow less

Investment suitability & Risk

Low risk

High risk

The Fund’s investment objective is to generate attractive and competitive capital growth in the long term. It is therefore particularly suited to investors with an investment horizon of at least 5 years who want to selectively diversify their portfolio with investments in the biotechnology sector and who are willing to accept the equity risks typical of this sector.

General Information

Investment ManagerBellevue Asset Management AG
CustodianRBC Investor Services, Luxembourg
Fund AdministratorRBC Investor Services, Luxembourg
AuditorPriceWaterhouseCoopers
Launch date02.04.2009
Year end closing30. Jun
NAV CalculationDaily "Forward Pricing"
Cut of time15:00 CET
Management Fee0.90%
Subscription Fee (max.)5.00%
ISIN numberLU0415392751
Valor number3882833
BloombergBBBIOUI LX
WKNA0X8YS
Total expense ratio (TER)2.22% (30.09.2021)

Legal Information

Legal formSICAV Luxembourg jurisdiction
SFDR categoryArticle 8

Key data (30.09.2021, base currency USD)

Beta0.89
Volatility25.80
Tracking error9.28
Active share43.88
Correlation0.94
Share ratio0.43
Information ratio-0.24
Jensen's alpha-1.13
No. of positions57

Top 10 positions

Gilead Sciences
Regeneron Pharma.
Moderna
Genmab
Vertex Pharmaceut.
Seagen
Illumina
Biogen Idec
Amgen
Horizon Therapeutics
5.8%
5.3%
5.0%
4.2%
4.1%
3.9%
3.4%
3.4%
3.4%
3.0%

Market capitalization

0 - 1 bn
1 - 2 bn
2 - 5 bn
5 - 15 bn
15 - 20 bn
> 20 bn
Others
2.3%
3.4%
12.2%
19.2%
4.8%
56.1%
2.1%

Geographic breakdown

United States
Denmark
Germany
China
Switzerland
Great Britain
Belgium
Japan
Others
Cash
73.1%
8.4%
3.3%
2.3%
2.0%
2.0%
1.8%
1.1%
4.2%
1.7%

Breakdown by sector

Oncology
Infectious Diseases
Orphan Drugs
Neurolog. Disorders
Pulmonary Diseases
Specialty Pharma
Life Science Supply
Central Nervous Syst.
Autoimmune disease
Metabolic Diseases
Others
Cash
31.8%
12.9%
8.1%
7.3%
4.1%
3.9%
3.4%
3.4%
2.8%
2.4%
18.3%
1.7%

Currency

USD
DKK
EUR
CHF
HKD
JPY
Others
83.1%
8.4%
3.1%
1.6%
1.3%
1.1%
1.5%

Opportunities

  • New innovative drugs are powering sustainable momentum in the biotech sector.
  • Attractively valued large-cap biotechs.
  • Expiring pharmaceutical patents trigger a rise in M&A activity.
  • Focus on US biotech companies with strong growth potential.
  • Bellevue has been a Healthcare pioneer since 1993 and is one of the biggest independent investors in the sector in Europe today.

Risks

  • Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
  • Market, industry or company factors can lead to strong short-term price fluctuations
  • The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
  • Investing in emerging markets entails the additional risk of political and social instability.
  • The fund may invest in financial instruments that might have a rather low level of liquidity, which can in turn affect the fund’s liquidity.

Stock markets were weak in September. The S&P 500 retreated 4.8%, the Nasdaq Biotech Index -4.9% and the BB Adamant Biotech (Lux) Fund -5.8% (USD / B shares).

The ramp-up of economic activity in many industrialized countries marked a new phase of the economic recovery. Although the rising number of Delta cases continues to have negative repercussions, the new restrictions being imposed on unvaccinated people are pushing vaccination rates higher. In addition, the Center for Disease Control (CDC) recommended vaccine booster shots for a large section of the US population, which is broader than the recommendation issued by an FDA advisory panel. In COVID-19 vaccine news, Pfizer/BioNtech has filed for FDA approval of its vaccine for 5-11 year-olds. Regeneron/Roche’s antibody cocktail demonstrated good efficacy against all virus variants, prompting the companies to submit the data for emergency use authorization (EUA) as a treatment for non-hospitalized COVID-19 patients. Supply chain bottlenecks in the aftermath of the pandemic are pushing up costs, but central bankers believe this pressure will not last. Budget talks in Washington coupled with wrangling over an infrastructure deal and social spending package once again put a political spotlight on drug prices as a way of raising money for the spending bills. It is expected that the federal health insurance programs will be authorized to negotiate drug prices on their own. At the European oncology conference (ESMO), presentations on antibody drug conjugates (ADC) were particularly impressive. The M&A carousel kept going round and round too. Sanofi took over Kadamon for USD 1.3 bn, a premium of 83%, and Merck bid USD 10.4 bn for Accelleron, offering a premium of 24%.

The following stocks made the best contribution to the portfolio's performance in September: Arcus Biosciences rose on data that a competitor presented at ESMO that was based on the same mechanisms of action (CD73 antibodies, adenosine); Innovent gained thanks to the pipeline data it presented at ESMO (anti-PD1 antibodies) and its multiple kinase inhibitor taletrectinib; Harmony was marked up after pitolisant was included in the updated AASM guidelines as a treatment for insomnia (narcolepsy); and IntraCellular Therapeutics published new data from its trial of Lumateperone in bipolar depression.

Performance detractors in September were Apellis, after a Phase III trial of pegcetacoplan for geographic atrophy and dry macular degeneration did not meet all the primary endpoints; Mersana corrected after releasing updated interim data from a Phase I trial of upifitamab rilsodotin in ovarian cancer that indicated reduced efficacy; and ZaiLabs sold off despite reporting good progress in its pipeline.

Our stance towards the biotech sector remains positive in view of its strong fundamentals and very attractive valuations (average 2022 P/E of 13x and PEG of 1.1 for large caps). These are still very attractive multiples compared to the biotech sector's historical valuations and the current ratios for the pharma sector (P/E 15x, PEG 2.3) and the S&P Index (P/E 20x, PEG 2.0).

The companies in our portfolio are working on technologies or products for novel treatment solutions. We are also invested in selected specialty pharma companies that offer high growth rates and moderate valuations. The Bellevue Biotech (Lux) Fund is well-positioned to profit from the milestones that are expected to be reached in 2021 and 2022. The regulatory environment favors the innovation coming out of biotech labs and the coronavirus crisis has improved the image of drug developers. Large pharma companies have acquired a number of companies in the fund's portfolio – Loxo, Array, Medicines Company, Myokardia and Alexion – and we expect more M&A deals to be announced during the coming months.

Past performance is not a reliable indicator of future results and can be misleading. As the sub-fund is denominated in a currency that may differ than an investor’s base currency, changes in the rate of exchange may have an adverse effect on prices and incomes. Performance is shown net of fees and expenses for the relevant share class over the reference period. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. Individual costs are not taken into account and would have a negative impact on the performance. With an investment amount of EUR 1,000 over an investment period of five years, the investment result in the first year would be reduced by the front-end load of up to EUR 50 (5%) as well as by additional individual custody charges. In subsequent years, the investment result would also be reduced by the individual custody account costs incurred. The reference benchmark of this class is used for performance comparison purposes only (dividend reinvested). No benchmark is directly identical to a sub-fund, thus the performance of a benchmark is not a reliable indicator of future performance of the sub-fund it is compared to. There can be no assurance that a return will be achieved or that a substantial loss of capital will not be incurred. All figures in base currency in %, calculated by the total return / BVI method.Show moreShow less

  • Lead Portfolio Manager

    Christian Lach

    After working as a member of the Management Team BB Biotech/ BB Medtech at Bellevue Asset Management AG until 2008, Christian Lach was Senior Portfolio Manager Biotechnology at Adamant Biomedical Investments AG. Since 2015, he has been working again at Bellevue Asset Management as Senior Portfolio Manager Healthcare Funds & Mandates. He holds a degree in natural sciences (Dipl. Natw. ETH) and a doctorate in economics from the University of St. Gallen (Dr. oec HSG).
  • Portfolio Manager

    Samuel Stursberg

    After receiving his Master of Science in Biochemistry from the University of Basel and a degree in Economics from the University of St. Gallen (lic. oec. HSG), Samuel Stursberg conducted stock analysis at Bank Sarasin among others and was Head Research at Adamant Biomedical Investments AG before joining Bellevue Asset Management as Head Research health Care Funds & Mandates in 2015.
  • Analyst

    Lukas Leu

    Lukas Leu has been a Healthcare Analyst at Bellevue Asset Management since 2021. He holds a PhD in biochemistry from the Swiss Federal Institute of Technology in Zurich. He previously worked as a research assistant at his alma mater and as an equity research analyst in the healthcare sector at Julius Baer.
1

These insights might interest you